|
About Us: |
GovernanceBoard of Trustees Philip K. Russell, M.D Dr. Russell is Professor Emeritus at Johns Hopkins School of Hygiene and Public Health, Department of International Health. He is board certified in internal medicine and has authored over 100 publications on infectious diseases. He retired in 1990 from the U.S. Army as Major General after a career in infectious disease research. His military assignments included Director, Walter Reed Army Institute of Research, and overseas tours in Pakistan, Thailand and Vietnam. He is the recipient of the Legion of Merit and the Distinguished Service Medal. Dr. Russell is Past President of the American Society of Tropical Medicine and Hygiene and a Fellow of the Infectious Disease Society of America. He served as Special Adviser to the International Children's Vaccine Initiative and now serves on the board of directors of the International AIDS Vaccine Initiative. He is a member of the Strategic Advisory Committee of the Bill and Melinda Gates Children's Vaccine Program and a consultant to the Bill and Melinda Gates Foundation. In November 2001, he was appointed to the new Office of Public Health Preparedness as special advisor on vaccine development and production. Mary Ann Chaffee Ms. Chaffee is Senior Vice President at Spectrum Science Communications. Formerly she was legislative strategist at The Glover Park Group, and legislative director and principal policy advisor to U.S. Senator Zell Miller. In a federal public service career spanning 20 years, she has worked on bills pertaining to Medicare, Medicaid, prescription drug benefits, biomedical research, preventive health services, and vaccines. She previously was policy advisor to Senator Dale Bumpers, when she formulated the Senator's agenda for such issues as government purchase and pricing of pediatric vaccines, childhood immunization, and global polio eradication. She holds a Master in Public Administration degree from Harvard University's John F. Kennedy School of Government. There she received Harvard’s Women’s Leadership Fellowship. She also earned a Master of Science degree from Case Western University, and a Bachelor of Arts from Ohio State University. Louis Z. Cooper, M.D. A past (2001-2002) President of the American Academy of Pediatrics, Dr. Cooper has been extensively involved in vaccine research since 1964. At Bellevue Hospital in New York, Dr. Cooper created the Rubella Project, a vaccine research program, which evolved into a multidisciplinary team dedicated to defining and resolving the rubella problem. This project enabled Dr. Cooper to translate scientific information into public policy, legislation and program building in health, education, and social services. Dr. Cooper served as Chairman of the Department of Pediatrics at St. Luke's-Roosevelt Hospital Center for 25 years, becoming Chair, Emeritus in 1998. He has served on numerous advisory bodies at the federal, state, and city level, including chairmanships of the Medical Society of the State of New York Committee on Medicaid and the Public Policy Committee (PPC) of the Pediatric Infectious Disease Society. He is also a member of the corresponding PPC of the Infectious Diseases Society of America. He was the founding Co-Chairman of the Campaign for Healthy Children, which is best known for designing, advocating, and facilitating implementation of the Child Health Plus Program, New York's effort to guarantee health insurance for every child in the state. Dr. Cooper is a graduate of Yale University and received his M.D. from Yale University School of Medicine. Ciro de Quadros, M.D., M.P.H. Before joining the Sabin Vaccine Institute in 2003, Dr. de Quadros was Director of the Division of Vaccines and Immunization of the Pan American Health Organization. He has also worked for the World Health Organization as Chief Epidemiologist for the Smallpox Eradication Program in Ethiopia. He pioneered development of surveillance and containment strategies for smallpox eradication and directed successful polio and measles eradication efforts for the Western Hemisphere. Dr. de Quadros is an Associate Adjunct Professor at the Johns Hopkins School of Hygiene and Public Health, an Associate Professor at the School of Medicine of Case Western Reserve University and an Adjunct Professor in the Department of Tropical Medicine at The George Washington University School of Medicine and Health Sciences. He completed his medical and public health studies in Brazil. Jeffrey A. Fuisz Mr. Fuisz is a partner in Kaye Scholer's Litigation Department and is resident in the firm's New York office. He represents clients in a broad range of litigations with a focus on complex commercial disputes, securities and bankruptcy-related litigation. Mr. Fuisz has been lead counsel in jury and bench trials in both state and federal courts and has broad experience in all phases of litigation. He brings advanced capabilities in the use of technology in the litigation process, including management of discovery and courtroom presentations. He co-chairs Kaye Scholer's E-Discovery Practice Group which offers clients innovative and real-world advice on managing electronic discovery in modern litigation. Allan L. Goldstein, Ph.D. Dr. Goldstein created the first Internet-based, live continuing medical education program, Frontiers in Biomedicine, the success of which led to a second program, Frontiers in Clinical Genetics. He developed and established the International Scientific Meeting, the Public Service and Scientific Achievement Awards and attracted over $15 million of new support to the George Washington University School of Medicine and Health Sciences. Previously, Dr. Goldstein served as President and Science Director at the Institute for Advanced Studies in Immunology and Aging. He founded and was Chairman and Chief Scientific Advisor of RegeneRx Inc., a public biotechnology company. He is the co-discoverer of thymosins, polypeptide hormones of the thymus gland, and has been issued eleven patents in connection with this discovery. Lance Gordon, Ph.D. Dr. Gordon is the former Chief Executive Officer, VaxGen, inventor of ProHibit® for infant meningitis, the first bacterial conjugate vaccine to receive FDA approval; prior to joining VaxGen, served as CEO and a member of the Board of Directors of OraVax and North American Vaccines; received his Ph.D. in Biomedical Science, Immunology from the University of Connecticut and completed his postdoctoral fellowship as an NIH fellow at the Division of Allergy and Immunology, Washington University Medical School, St. Louis.
Alan E. Greenberg, M.D., M.P.H. Alan E. Greenberg is Professor and Chair of the Department of Epidemiology and Biostatistics as well as Professor in the Departments of Medicine and of Microbiology, Immunology, and Tropical Medicine in the George Washington University's School of Medicine and Health Sciences. He is involved in a large number of projects and activities, including his role as co-founder and co-director of the GW HIV/AIDS Institute, dedicated to linking and expanding the University's HIV-related research and educational activities in basic science, prevention, epidemiology, clinical care, education and health policy. Prior to returning to GWU, where he earned his MD degree, Dr. Greenberg spent two decades at the Centers for Disease Control and Prevention, where he provided scientific leadership for its domestic and international HIV epidemiologic research program. He served as chief of the agency's HIV Epidemiology Branch, supervising research studies in 28 U.S. states and nine countries. His assignments have taken him around the globe, including Cote d'Ivoire, where he spent four years directing the CDC's research, training and clinical services in West Africa. Dr. Greenberg's coauthored manuscripts cover a wide range of issues, including various aspects of HIV transmission; laboratory diagnostics; molecular epidemiology; and the relationships between sexually transmitted diseases, tuberculosis, malaria and HIV. Dr. Greenberg also serves on the editorial board of the journal AIDS. Professor Greenberg has received numerous awards, including the Outstanding Service Medal from the U.S. Public Health Service and the Secretary's Award for Distinguished Services from the Department of Health and Human Services. A board-certified internist, Dr. Greenberg currently serves as a voluntary HIV/AIDS physician at the infectious diseases clinic of the Veterans Administration Medical Center in Washington. He has chaired and participated in numerous NIH Review Panels and lectures frequently on domestic and international HIV/AIDS epidemiology.
Axel Hoos, M.D., Ph.D. Dr. Axel Hoos studied medicine at Heidelberg University, Heidelberg, Germany and received his PhD in molecular oncology for work in molecular biology and tumor immunology at the German Cancer Research Center in Heidelberg. He trained in surgery with a focus on surgical oncology at the Technical University in Munich and worked in surgery, molecular pathology and cancer immunology at Memorial Sloan-Kettering Cancer Center in New York. Subsequently, Dr. Hoos was Senior Director, Clinical Development at Antigenics Inc., a biotechnology company with focus on vaccines for cancer and infectious diseases, where he was responsible for developmental strategy and clinical trials in all phases of product development. Recently, he joined Bristol-Myers Squibb as Medical Lead in Immunology/Oncology with responsibility for the Ipilimumab (anti CTLA-4) immunotherapy program.
Peter Hotez M.D.,
Ph.D (ex oficio) In addition to being president of Sabin Vaccine Institute, Peter Hotez is the Walter
G. Ross Professor and Chair of the Department of Microbiology, Immunology and
Tropical Medicine at The George Washington University, where his major research
and academ Dr. Hotez is a native of Hartford, Connecticut. He obtained his B.A. degree in Molecular Biophysics Phi Beta Kappa from Yale University (1980) and his M.D. and Ph.D. from the medical scientist-training program at Weill Cornell Medical College and The Rockefeller University. After completing his residency at the Massachusetts General Hospital, Dr. Hotez returned to Yale University where he was on the faculty for 12 years, before joining GWU in 2000.
Mr. Morton Hyman Mr. Morton Hyman has been a leader both in the business world and in the public health sector since 1971. In the private Walter Orenstein, M.D. Dr. Orenstein is Professor of Medicine and Pediatrics at Emory University School of Medicine, serving as director of the Program for Vaccine Policy and Development and associate director of the Vaccine Center. He is immediate past director of the Kevin L. Reilly Mr. Reilly was President of Wyeth Vaccines and Nutrition from 1999 to 2002. Prior to joining the vaccine division, Mr Adan Rios, M.D. Dr. Adan Rios was born in Panama City, Republic of Panama. He completed his medical degree at the University of Panama, a specialty in internal medicine at Gorgas US Army Hospital, and a fellowship in medical oncology at the MD Anderson Cancer Center, where he then worked for several years. Dr. Rios was the director of clinical research and academic affairs of the Institute for Immunological Disorders, the first clinical center devoted to the management and treatment of AIDS patients in the USA. He founded the Houston Conference on AIDS in America, which became one of the most important national conferences on AIDS in the nation. Dr. Rios has written in the fields of tumor immunology, cancer, and AIDS and did the confirmatory work of the activity of interferon in AIDS-related Kaposi's Sarcoma. He is an adjunct professor in the Department of Microbiology, Tropical Medicine, and Immunology at The George Washington University School of Medicine and Health Sciences and is president of Oncol Therapeutics, based in Houston, Texas, where he resides.
Dr. Scott became a full professor in the Department of Emergency Medicine in 1998. Previously, he served as residency director, Assistant Dean for Graduate Medical Education, and Assistant Dean for Student Affairs in SMHS. Each spring the fourth year medical students select a clinical professor to receive the Golden Apple award for outstanding teaching. Dean Scott has received this award 10 times between 1986 and 2003. Dr. Scott's research is primarily in the areas of graduate and post-graduate education including toxicology, communication with families of trauma patients, and international graduate medical education. He also has a background in violence prevention and telemedicine. Dr. Scott received his bachelor's degree from the University of Notre Dame in 1977 followed by serving in the Peace Corps. He received his medical degree from the University of Arizona College of Medicine in 1983. Dr. Scott completed his internal medicine internship at the University of Arizona and did his emergency medicine residency at The George Washington University. He has served as the Dean of the School of Medicine and Health Sciences (SMHS) since the summer of 2003. H. R. Shepherd, D.Sc. Dr. Shepherd is Founding Chairman of the Sabin Vaccine Institute. In addition, he is an Adjunct Professor at The George Washington University. Previously he was Chairman and CEO of Armstrong Pharmaceuticals, Inc., which he founded as Aerosol Techniques in 1955. A world-recognized expert on aerosol medications, he holds several patents on aerosol products and spearheaded the development of the metered dose inhaler. He led a successful effort to fund the nation's first research laboratory dedicated to aerosol pharmaceuticals at Columbia University College of Pharmacy. He is the author of Aerosols: Science and Technology, the first definitive text on the potential of aerosol medications.
Michael E. Whitham Michael E. Whitham has worked with numerous universities, non-profit research institutions and charitable foundations on patent, trademark, licensing, and contract matters over the last fifteen years. Mr. Whitham previously served as Partner with McGuireWoods, LLP, and as Chief Financial Officer and Partner at Whitham, Curtis & Whitham, PLC. He is a member of the Association of University Technology Managers, the American Bar Association, the American Intellectual Property Law Association, the American Trial Lawyers Association, the Licensing Executives Society, and the American Chemical Society. |
 | “A
scientist who is also a human being cannot rest | |
|---|
sector he is the founder and director of MPH Enterprises LLC, and from 1969 to 2003 was a Director and Officer of Overseas Shipholding Group, a company that owns and operates of one of the world’s largest fleets of ocean-going vessels engaged in the transportation of oil and petroleum products in the domestic and international markets. He was President and CEO of the company from 1999 until his retirement in 2003. Mr. Hyman has been a leader in public health since being asked to become a member of New York State's Public Health Council in 1971. He was Chairman of the Board of Trustees of Beth Israel Medical Center from 1985 to 2007 and Chairman of the Board of Trustees of Continuum Health Partners from 1997 to 2007, as well as serving on the board of several other prestigious organizations including St. Luke's-Roosevelt Hospital Center, Long Island College Hospital, New York Eye and Ear Infirmary, and the Albert Einstein College of Medicine of Yeshiva University. Mr. Hyman has won a variety of esteemed awards including an honorary Doctor of Human Letters degree from New York Medical College, the 2002 Leadership in Business Award from the New York Business Group on Health, and the Ellis Island Medal of Honor. Mr. Hyman earned the degree of Doctor of Laws from Cornell University in 1959, and completed his bachelor's degree there as well in 1956. 
Centers for Disease Control and Prevention’s National Immunization Program (NIP), where he is credited with attaining the highest immunization levels ever in U.S. children; eliminating indigenous transmission of measles; introduction of hepatitis B, Hib, rotavirus, varicella, and pneumococcal conjugate vaccines; and involving the CDC in the global polio eradication initiative. Dr. Orenstein has served in leadership roles within the CDC’s immunization program from 1982 to 2004, and from 1993 was Director of the National Immunization Program. He has served as a consultant to the World Health Organization and to the Pan American Health Organization (PAHO) for programs in polio eradication, measles control, and smallpox eradication in India, Brazil, Argentina, and Peru. Dr. Orenstein served as an Assistant Surgeon General of the U.S. Public Health Service, and he currently serves as chairman of the World Health Organization’s Technical Consultative Group on the Global Eradication of Poliomyelitis, and as a member of the International Editorial Board for the journal, Vaccine. He is fellow of the American Academy of Pediatrics, the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society.
. Reilly was President of Wyeth Nutrition International from 1996 to 1998, and was responsible for management and direction of the business worldwide. During his rise through Wyeth, Mr. Reilly held the positions of Group Vice President from 1994 to 1996, and Area Vice President from 1991 to 1994 for the Pacific Rim Group, an area that encompasses the Philippines, Australia, New Zealand, India and Pakistan. Mr. Reilly began his career at Connaught Laboratories, Ltd. as a Senior Vice President in charge of Canadian and export operations from 1973 to 1984. Mr. Reilly earned a Bachelor of Science degree from the University of Melbourne in 1963 and a Master of Business Administration degree from York University, Toronto in 1973. Mr. Reilly is also a 1981 graduate of the Advanced Management Program at Harvard Business School.
